A185490 Stock Overview
Engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
EyeGene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,615.00 |
| 52 Week High | ₩4,720.00 |
| 52 Week Low | ₩2,430.00 |
| Beta | 1.52 |
| 1 Month Change | -8.57% |
| 3 Month Change | -15.65% |
| 1 Year Change | -38.69% |
| 3 Year Change | -86.31% |
| 5 Year Change | -72.47% |
| Change since IPO | -76.05% |
Recent News & Updates
Shareholder Returns
| A185490 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.2% | -2.3% | -1.9% |
| 1Y | -38.7% | 14.9% | -9.5% |
Return vs Industry: A185490 underperformed the KR Biotechs industry which returned 14.9% over the past year.
Return vs Market: A185490 underperformed the KR Market which returned -9.5% over the past year.
Price Volatility
| A185490 volatility | |
|---|---|
| A185490 Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A185490 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A185490's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 41 | Won-Il Yoo | www.eyegene.co.kr |
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company’s products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculosis vaccine; and EG-HPV that has completed Phase I clinical trial for the treatment of cervical cancer. It also offers EG-Vac for the treatment of immune adjuvant; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-HZ, which has completes phase I trials for the treatment of herpes zoster.
EyeGene Inc. Fundamentals Summary
| A185490 fundamental statistics | |
|---|---|
| Market cap | ₩70.68b |
| Earnings (TTM) | -₩14.09b |
| Revenue (TTM) | ₩3.26b |
21.7x
P/S Ratio-5.0x
P/E RatioIs A185490 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A185490 income statement (TTM) | |
|---|---|
| Revenue | ₩3.26b |
| Cost of Revenue | ₩1.58b |
| Gross Profit | ₩1.68b |
| Other Expenses | ₩15.77b |
| Earnings | -₩14.09b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -521.33 |
| Gross Margin | 51.43% |
| Net Profit Margin | -432.54% |
| Debt/Equity Ratio | 6.0% |
How did A185490 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 20:37 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EyeGene Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| JooYong Kim | Kiwoom Securities Co., Ltd. |
| Jiyong Lee | Shinhan Investment Corp. |